Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy
Shots:
- Dewpoint to receive up front payment and up to $239M as research- development & commercial milestones along with royalties on sales of the therapies
- The companies collaborated for the development of therapies to treat DM1
- The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs
Ref: PRNewswire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
